These lead to changes in key metabolic pathways, including inhibition of lipoprotein lipase, peroxisome proliferator-activated receptor-gamma (PPARꝩ) and glucose transporter (GLUT4), resulting in dyslipidemia, weight changes and dysglycemia [113, 114]. This evidence concerns the gene SLC2A4 and metabolic syndrome.